The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

The invention provides a method of treating a disorder characterised by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.

The present invention relates to methods for modulating the Wnt signaling pathway using compounds of Formula (1),

##STR00001## wherein A.sup.1, Y and Z all represent rings.

Plasma kallikrein binding proteins and methods of using such proteins are described.

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.

Provided is an inorganic composite compound having reduced oxygen and a high reducing ability, which includes elements having a positive atomic valence of a plant-derived component and a sulfur compound. The compound provides a therapeutic treatment effect and a pharmacological effect and is useful to suppress the influence of active oxygen (oxidization) and cannot be produced by a synthetic chemical technique. A method of producing the same is also provided.

Tricyclic chemical modulators of FOXO transcription factor proteins are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following and similar genera:

##STR00001##

in which Het is an aromatic heterocyclic ring and Y is a point of attachment of various side chains and rings. An example of such a compound is 4-chloro-N-(3-(10,11-dihydro-5H-benzo[b]pyrido[2,3-f]azepin-5-yl)propyl)benzenesulfonamide:

##STR00002##

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.

The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.

The dual microbial preparation contains the microscopic oomycete Pythium oligandrum and components of a physiological microbiome. The microscopic oomycete Pythium oligandrum and the physiological microbiome component are present in the dual preparation in a form which facilitates their germination, subsequent propagation and colonization of the target tissues. The microscopic oomycete Pythium oligandrum is incorporated in a quantity of 10.sup.3 to 10.sup.7 CFU (colony forming units), with 10.sup.4 to 10.sup.5 CFU per one cycle of application preferably. The physiological microbiome component contains 5×10.sup.6 to 5×10.sup.10 CFU, with 5×10.sup.7 to 5×10.sup.9 per one cycle of application preferably. The fermented substrate found in the Pythium oligandrum oomycete is the source of nutrients for both microbial components. The dual microbial preparation also contains at least one auxiliary substance from a group including a desiccant, components of a buffer system, an anti-caking substance and an agent for the creation of a physiological osmotic environment. The physiological microbiome component is a component of the human microbiome, one of the microbes of the green complex, such as the Capnocytophaga sputigena bacterium, or one of the components of the healthy skin microbiome, such as the Staphyloccocus epidermidis bacterium, or one of the components of the healthy vaginal microbiome, such as the peroxide producing Lactobacillus crispatus. Either the microscopic oomycete Pythium oligandrum or the physiological microbiome component is present in the dual microbial preparation in the form of inactivated cells, cell extracts or isolated cell fractionation. The microbial activator for the Pythium oligandrum oomycete is a yeast autolysate in a quantity of 0.1% to 10% weight of the total quantity of dual microbial preparation. The auxiliary substances are regulated in a way which allows for application in the form of an ointment, cream, oil or suppository or in the form of a liquid aqueous preparation.